Market Cap 5.16B
Revenue (ttm) 376.57M
Net Income (ttm) -77.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -20.63%
Debt to Equity Ratio 0.03
Volume 3,938,800
Avg Vol 1,663,232
Day's Range N/A - N/A
Shares Out 62.27M
Stochastic %K 96%
Beta 2.23
Analysts Strong Sell
Price Target $75.00

Company Profile

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing,...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 800 719 0671
Address:
681 Gateway Boulevard, South San Francisco, United States
B2iDigital
B2iDigital Jun. 19 at 2:15 PM
eXoZymes says its platform can also produce cannabinoids, terpenes, and flavonoids. A May 2026 investor presentation from eXoZymes (Nasdaq: $EXOZ ) put the spotlight on the wider range of compounds its platform can make. Chairman Chris Marlett said cannabinoids are next in line, with terpenes and flavonoids behind them, and that the company is building its patents around the methods used to make these compounds. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Marlett traced the cannabinoid work back to the company’s earliest days: “So cannabinoids are next. Actually, ironically, it was the first thing we started to make. We started to make cannabinoids. We got grants to make it and we demonstrated that we could get yields.” The presentation also covered: • A platform the company says also extends to terpenes and flavonoids • A strategy to patent the methods used to make natural compounds, plus composition patents on engineered analogs and enzymes • A partnership model spanning contract manufacturers, supplement makers, and pharmaceutical companies • Recognition in scientific and news publications and grant funding the company cites as validation Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology. The company is building a pipeline of natural compounds and engineered analogs across nutraceutical and pharmaceutical applications. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
LewisDaKat
LewisDaKat Jun. 19 at 11:30 AM
$TWST The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own https://marketwirenews.com/stock/twst/news/the-next-wave-of-medical-ai-could-mint-more-milliona-7723724229539318.html?utm_source=stocktwits
0 · Reply
iwtd
iwtd Jun. 18 at 9:53 AM
$TWST - Twist Bioscience Corporation. Breaking out with cup with handle pattern. 1st price target is 90$ and once that is reached the second target would be 104$. Weekly chart posted here.
0 · Reply
WOLFSTREET
WOLFSTREET Jun. 17 at 2:40 PM
$TWST OMG! Is it time for this yet? On my street @WOLFSTREET , we knew this was coming in 2025 when I started sharing CC Data LO-LO-LO 20s,30s, even 40s... actually, I have never stopped. See, every post I share is 100% Certified and Backed by CC9.8, making this process a no brainer. That's right, U and ME do not need a brain in stock market activities since that would only screw things up. CC guided $ROKU to 100%++ gains with absolutely ZERO effort and all of it was posted right here!
0 · Reply
handmedown1
handmedown1 Jun. 16 at 8:00 PM
$TWST is killing it. $CRSP take a clue.
0 · Reply
topstockalerts
topstockalerts Jun. 16 at 5:25 PM
TD Cowen named Twist Bioscience its top small- and mid-cap investment idea, highlighting the company as an underappreciated opportunity in life sciences tools. The firm cited Twist’s strong year-to-date performance and its strategic positioning at the intersection of multiple growth drivers, including expanding demand from AI-enabled drug discovery and life sciences research. Twist operates a silicon-based DNA synthesis platform that delivers low-cost, high-throughput DNA used across next-generation sequencing (NGS) and synthetic biology applications. TD Cowen noted that NGS already accounts for more than half of total revenue and is showing early signs of AI-driven order acceleration, particularly from biotech and pharma R&D teams. The firm views AI-related demand as a multi-year tailwind rather than a short-term spike. $TWST
0 · Reply
DBRGLong
DBRGLong Jun. 16 at 3:50 PM
$TWST as of 5/29, the Short % was 24.31%, with 14.9M shares short, & 8.8 days to cover. This epic run for TWST is fueling a very tough situation for our short friends... for us Longs however? Based upon TWST's float & average trading volume, it will be starting to become more & more difficult for our short friends to potentially exit their short positions quickly without continuing to push the stock price for TWST higher. Add in positive catalysts like them continuing to be on track for their EBITDA breakeven objective later this year, & we have A LOT in our favor when it comes to more & more potential upward momentum for TWST 🥂
0 · Reply
WOLFSTREET
WOLFSTREET Jun. 16 at 12:45 PM
$TWST Was there ever any doubt? I use CC9.8, what do you do, draw silly lines? I hope not.
0 · Reply
RemitTekram
RemitTekram Jun. 15 at 9:04 PM
$TWST My teen shares are all grown up. I’m very proud of them.
0 · Reply
notreload_ai
notreload_ai Jun. 15 at 11:42 AM
Canaccord is bullish on $TWST, citing AI-driven DNA tech growth, strong revenue gains, and upside to $90 target. https://notreload.xyz/xy/twst-stock-surges-toward-1b-goal-as-canaccord-joins-bullish-chorus/
0 · Reply
Latest News on TWST
Twist Bioscience files automatic mixed securities shelf

2026-06-18T20:15:47.000Z - 21 hours ago

Twist Bioscience files automatic mixed securities shelf


Ozempic Linked To Lower Risk Of Violence In New Study

Jun 17, 2026, 11:45 AM EDT - 2 days ago

Ozempic Linked To Lower Risk Of Violence In New Study

AZN LLY NVO


Twist Bioscience initiated with a Buy at Canaccord

2026-06-15T09:45:05.000Z - 4 days ago

Twist Bioscience initiated with a Buy at Canaccord


Twist Bioscience Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 17 days ago

Twist Bioscience Slides: Corporate presentation


Twist Bioscience Transcript: Investor Day 2026

May 21, 2026, 2:00 PM EDT - 4 weeks ago

Twist Bioscience Transcript: Investor Day 2026


Twist Bioscience Slides: FY 2026

May 21, 2026, 2:00 PM EDT - 4 weeks ago

Twist Bioscience Slides: FY 2026


Twist Bioscience price target raised to $65 from $50 at Baird

2026-05-05T10:43:55.000Z - 6 weeks ago

Twist Bioscience price target raised to $65 from $50 at Baird


Twist Bioscience Earnings Call Transcript: Q2 2026

May 4, 2026, 8:00 AM EDT - 6 weeks ago

Twist Bioscience Earnings Call Transcript: Q2 2026


Twist Bioscience Earnings release: Q2 2026

May 4, 2026, 8:00 AM EDT - 6 weeks ago

Twist Bioscience Earnings release: Q2 2026


Twist Bioscience Slides: Q2 2026

May 4, 2026, 8:00 AM EDT - 6 weeks ago

Twist Bioscience Slides: Q2 2026


Twist Bioscience Quarterly report: Q2 2026

May 4, 2026, 8:00 AM EDT - 6 weeks ago

Twist Bioscience Quarterly report: Q2 2026


Twist Bioscience reports Q2 EPS (71c) vs. (66c) last year

2026-05-04T11:23:13.000Z - 6 weeks ago

Twist Bioscience reports Q2 EPS (71c) vs. (66c) last year


Twist Bioscience to Present at Upcoming Investor Conferences

Feb 18, 2026, 8:00 AM EST - 4 months ago

Twist Bioscience to Present at Upcoming Investor Conferences


Twist Bioscience Slides: Corporate presentation

Feb 17, 2026, 7:00 AM EST - 4 months ago

Twist Bioscience Slides: Corporate presentation


Twist Bioscience Transcript: AGM 2026

Feb 5, 2026, 10:00 AM EST - 4 months ago

Twist Bioscience Transcript: AGM 2026


Twist Bioscience Earnings Call Transcript: Q1 2026

Feb 2, 2026, 8:00 AM EST - 4 months ago

Twist Bioscience Earnings Call Transcript: Q1 2026


Twist Bioscience Quarterly report: Q1 2026

Feb 2, 2026, 8:00 AM EST - 4 months ago

Twist Bioscience Quarterly report: Q1 2026


Twist Bioscience Earnings release: Q1 2026

Feb 2, 2026, 8:00 AM EST - 4 months ago

Twist Bioscience Earnings release: Q1 2026


Twist Bioscience Slides: Q1 2026

Feb 2, 2026, 8:00 AM EST - 4 months ago

Twist Bioscience Slides: Q1 2026


Twist Bioscience Proxy statement: Proxy Filing

Jan 6, 2026, 7:00 AM EST - 5 months ago

Twist Bioscience Proxy statement: Proxy Filing


Can Twist Bioscience Drop More?

Nov 17, 2025, 9:25 AM EST - 7 months ago

Can Twist Bioscience Drop More?


Twist Bioscience Earnings Call Transcript: Q4 2025

Nov 14, 2025, 8:00 AM EST - 7 months ago

Twist Bioscience Earnings Call Transcript: Q4 2025


Twist Bioscience Annual report: Q4 2025

Nov 14, 2025, 8:00 AM EST - 7 months ago

Twist Bioscience Annual report: Q4 2025


Twist Bioscience Earnings release: Q4 2025

Nov 14, 2025, 8:00 AM EST - 7 months ago

Twist Bioscience Earnings release: Q4 2025


Twist Bioscience Slides: Q4 2025

Nov 14, 2025, 8:00 AM EST - 7 months ago

Twist Bioscience Slides: Q4 2025


Twist Bioscience Slides: FY 2025

Sep 9, 2025, 9:40 AM EDT - 10 months ago

Twist Bioscience Slides: FY 2025


Twist Bioscience Collaborates with Synthetic Design Lab

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Twist Bioscience Collaborates with Synthetic Design Lab


Twist Bioscience Earnings Call Transcript: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 11 months ago

Twist Bioscience Earnings Call Transcript: Q3 2025


Twist Bioscience Quarterly report: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 11 months ago

Twist Bioscience Quarterly report: Q3 2025


Twist Bioscience Earnings release: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 11 months ago

Twist Bioscience Earnings release: Q3 2025


Twist Bioscience Slides: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 11 months ago

Twist Bioscience Slides: Q3 2025


Twist Bioscience Slides: Corporate Presentation

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Twist Bioscience Slides: Corporate Presentation


Twist Bioscience and Ginkgo Bioworks Revise Collaboration

May 8, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

DNA


Twist Bioscience Earnings Call Transcript: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings Call Transcript: Q2 2025


Twist Bioscience Quarterly report: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Quarterly report: Q2 2025


Twist Bioscience Earnings release: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings release: Q2 2025


Twist Bioscience Slides: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Slides: Q2 2025


Twist Bioscience Earnings Call Transcript: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings Call Transcript: Q1 2025


Twist Bioscience Quarterly report: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Quarterly report: Q1 2025


Twist Bioscience Earnings release: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings release: Q1 2025


Twist Bioscience Slides: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Slides: Q1 2025


Twist Bioscience Proxy statement: Proxy Filing

Jan 6, 2025, 7:00 AM EST - 1 year ago

Twist Bioscience Proxy statement: Proxy Filing


Twist Bioscience Proxy statement: Proxy Filing

Dec 26, 2024, 7:00 AM EST - 1 year ago

Twist Bioscience Proxy statement: Proxy Filing


Twist Bioscience Earnings Call Transcript: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings Call Transcript: Q4 2024


Twist Bioscience Annual report: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Annual report: Q4 2024


Twist Bioscience Earnings release: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings release: Q4 2024


Twist Bioscience Slides: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Slides: Q4 2024


B2iDigital
B2iDigital Jun. 19 at 2:15 PM
eXoZymes says its platform can also produce cannabinoids, terpenes, and flavonoids. A May 2026 investor presentation from eXoZymes (Nasdaq: $EXOZ ) put the spotlight on the wider range of compounds its platform can make. Chairman Chris Marlett said cannabinoids are next in line, with terpenes and flavonoids behind them, and that the company is building its patents around the methods used to make these compounds. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Marlett traced the cannabinoid work back to the company’s earliest days: “So cannabinoids are next. Actually, ironically, it was the first thing we started to make. We started to make cannabinoids. We got grants to make it and we demonstrated that we could get yields.” The presentation also covered: • A platform the company says also extends to terpenes and flavonoids • A strategy to patent the methods used to make natural compounds, plus composition patents on engineered analogs and enzymes • A partnership model spanning contract manufacturers, supplement makers, and pharmaceutical companies • Recognition in scientific and news publications and grant funding the company cites as validation Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology. The company is building a pipeline of natural compounds and engineered analogs across nutraceutical and pharmaceutical applications. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
LewisDaKat
LewisDaKat Jun. 19 at 11:30 AM
$TWST The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own https://marketwirenews.com/stock/twst/news/the-next-wave-of-medical-ai-could-mint-more-milliona-7723724229539318.html?utm_source=stocktwits
0 · Reply
iwtd
iwtd Jun. 18 at 9:53 AM
$TWST - Twist Bioscience Corporation. Breaking out with cup with handle pattern. 1st price target is 90$ and once that is reached the second target would be 104$. Weekly chart posted here.
0 · Reply
WOLFSTREET
WOLFSTREET Jun. 17 at 2:40 PM
$TWST OMG! Is it time for this yet? On my street @WOLFSTREET , we knew this was coming in 2025 when I started sharing CC Data LO-LO-LO 20s,30s, even 40s... actually, I have never stopped. See, every post I share is 100% Certified and Backed by CC9.8, making this process a no brainer. That's right, U and ME do not need a brain in stock market activities since that would only screw things up. CC guided $ROKU to 100%++ gains with absolutely ZERO effort and all of it was posted right here!
0 · Reply
handmedown1
handmedown1 Jun. 16 at 8:00 PM
$TWST is killing it. $CRSP take a clue.
0 · Reply
topstockalerts
topstockalerts Jun. 16 at 5:25 PM
TD Cowen named Twist Bioscience its top small- and mid-cap investment idea, highlighting the company as an underappreciated opportunity in life sciences tools. The firm cited Twist’s strong year-to-date performance and its strategic positioning at the intersection of multiple growth drivers, including expanding demand from AI-enabled drug discovery and life sciences research. Twist operates a silicon-based DNA synthesis platform that delivers low-cost, high-throughput DNA used across next-generation sequencing (NGS) and synthetic biology applications. TD Cowen noted that NGS already accounts for more than half of total revenue and is showing early signs of AI-driven order acceleration, particularly from biotech and pharma R&D teams. The firm views AI-related demand as a multi-year tailwind rather than a short-term spike. $TWST
0 · Reply
DBRGLong
DBRGLong Jun. 16 at 3:50 PM
$TWST as of 5/29, the Short % was 24.31%, with 14.9M shares short, & 8.8 days to cover. This epic run for TWST is fueling a very tough situation for our short friends... for us Longs however? Based upon TWST's float & average trading volume, it will be starting to become more & more difficult for our short friends to potentially exit their short positions quickly without continuing to push the stock price for TWST higher. Add in positive catalysts like them continuing to be on track for their EBITDA breakeven objective later this year, & we have A LOT in our favor when it comes to more & more potential upward momentum for TWST 🥂
0 · Reply
WOLFSTREET
WOLFSTREET Jun. 16 at 12:45 PM
$TWST Was there ever any doubt? I use CC9.8, what do you do, draw silly lines? I hope not.
0 · Reply
RemitTekram
RemitTekram Jun. 15 at 9:04 PM
$TWST My teen shares are all grown up. I’m very proud of them.
0 · Reply
notreload_ai
notreload_ai Jun. 15 at 11:42 AM
Canaccord is bullish on $TWST, citing AI-driven DNA tech growth, strong revenue gains, and upside to $90 target. https://notreload.xyz/xy/twst-stock-surges-toward-1b-goal-as-canaccord-joins-bullish-chorus/
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 13 at 11:20 AM
Cathie Wood Goes All-In On SpaceX Debut, Dumps Rocket Lab Stock The Same Day $SPCX $RKLB $TER $HOOD $TWST https://stocktwits.com/news/equity/markets/spacex-cathie-wood-arkinvest-rocketlabs-sale/cZKITFqR75p
4 · Reply
DBRGLong
DBRGLong Jun. 13 at 12:21 AM
$TWST terrific week for us - looking forward to $80+ in the coming weeks - wishing a great weekend to all in the meantime 🥂
0 · Reply
LewisDaKat
LewisDaKat Jun. 12 at 8:30 PM
$TWST Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors. https://marketwirenews.com/stock/twst/news/twist-bioscience-director-sold-12-000-shares-here-s--7816890007797161.html?utm_source=stocktwits
0 · Reply
B2iDigital
B2iDigital Jun. 12 at 5:53 PM
eXoZymes names NCT, a compound tied to fat metabolism, as its lead molecule. NCT, a naturally occurring compound tied to how the body stores and burns fat, is the lead molecule for eXoZymes Inc. (NASDAQ: EXOZ). In a May 2026 investor presentation, Chairman Chris Marlett described how the company is pursuing it for markets such as obesity, type 2 diabetes, and fatty liver on both a nutraceutical and a pharmaceutical track. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 On what NCT does in the body, Marlett said: “...we see NCT as sort of a master metabolic switch that activates this pathway that really ramps up mitochondrial metabolization of fats and energy in your body and really could address the root of how the body stores and burns stored fat.” Marlett also noted: • Early data the company says points to measurable metabolic effects tied to NCT • A planned over the counter nutraceutical path, with market entry targeted following GRAS work • A parallel pharmaceutical path built around more potent NCT analogs • Interest from pharmaceutical companies exploring complements to GLP-1 therapies, per the company Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company applying AI engineered enzymes to produce natural molecules at scale. Its lead molecule, NCT, is being pursued on both a nutraceutical and a pharmaceutical track. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
FibonacciTrader_
FibonacciTrader_ Jun. 12 at 2:14 PM
$SPCX IPO WATCH — $135 | $2T LONG-TERM STORY Target narrative: 100x–200x potential by 2035 (if execution matches scale) These are the real ecosystem beneficiaries of SpaceX + Starshield + orbital expansion: $ARQQ → 12 Quantum encryption securing classified Starshield orbital networks $TWST → 74 Synthetic biology tools supporting long-term space + Mars life support R&D $LUNR → 30 NASA lunar lander tech aligned with future Moon base infrastructure $AEVA → 24 LiDAR + sensing systems enabling autonomous landing + booster recovery precision SpaceX is the platform - but value flows to the ecosystem around it. I’m looking to accumulate $SPCX on weakness for long-term positioning, not chasing IPO strength. Who else is building a space basket instead of betting on just one name?
2 · Reply
DBRGLong
DBRGLong Jun. 11 at 8:55 PM
$TWST crazy buying volume into the close once again
0 · Reply
11thestate
11thestate Jun. 11 at 2:55 PM
$TWST Settlement FAQ: Everything Investors Need to Know About the $17.05M Recovery Q: What happened? A: Twist Bioscience Corporation has reached a tentative settlement to resolve investor claims that it overstated the automation, quality, and profitability of its synthetic DNA and NGS tool business. Q: Am I actually eligible? A: If you bought $TWST shares between December 20 2018 and November 15 2022 , you’re likely eligible. You don’t need to hold the stock still to claim; past losses count Q: How much will I actually get? A: The current estimated payout is $0.31 per share. The final amount depends on how many people file; if fewer people claim, the payout per share can actually increase for those who did Q: When do payouts happen? A: Typically, within 4–9 months after the claim deadline. But the exact timing depends on the court and settlement administration. Q: Is my data safe with 11th Estate? A: Security is our top priority. We use bank-level encryption and are SOC2-compliant. We only process the trade data required for the court audit, and your personal financial credentials stay private. Q: What is the fee? A: We work on a 20% success fee. We handle the math, the paperwork, and the filing. If you don't get a payout, you don't pay us a cent. Q: How do I start? A: Just click the link below to submit your claim through our secure portal. https://11th.com/cases/twist-investor-settlement
0 · Reply
DBRGLong
DBRGLong Jun. 11 at 2:24 PM
$TWST - $85? We'll take it! https://www.gurufocus.com/news/8911631/twst-initiates-coverage-on-piper-sandler-rating-set-to-overweight
0 · Reply
DBRGLong
DBRGLong Jun. 9 at 8:55 PM
$TWST amazing - so that is now two days in a row where there is ferocious buying volume right up until the close, to get us back above $70, & back in the green. Dearest TWST, you continue to be my favorite holding YTD 🥂
0 · Reply
B2iDigital
B2iDigital Jun. 9 at 7:13 PM
eXoZymes (Nasdaq: $EXOZ ) announced the pricing of a public offering expected to generate approximately $5.3 million in gross proceeds, with funding intended to support development of its NCT program, continued R&D, and general corporate initiatives. For investors following eXoZymes, the announcement is significant because it provides additional capital to advance the company's AI-enabled exozyme platform and its efforts to scale production of high-value molecules for nutraceutical, pharmaceutical, and specialty chemical markets. eXoZymes is focused on using engineered enzymes operating outside living cells to manufacture complex molecules at commercial scale, an approach the company believes can overcome limitations associated with traditional biomanufacturing methods. Read the full announcement: https://exozymes.com/blog/fundraise-pricing-2026 eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1. Disclosure: This post is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation to purchase EXOZ or any other security. David Shapiro, CEO of B2i Digital, personally purchased shares of unrestricted EXOZ stock in the open market as part of B2i Digital's practice of investing alongside its Featured Companies. Investors should conduct their own due diligence and consult qualified financial and professional advisors before making any investment decisions. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
DBRGLong
DBRGLong Jun. 8 at 10:01 PM
$TWST furious volume into the close to get us back above $70+ 🥂
0 · Reply
B2iDigital
B2iDigital Jun. 5 at 6:03 PM
eXoZymes uses AI engineered enzymes to make natural molecules outside the living cell. Chris Marlett, Chairman of the Board of eXoZymes (Nasdaq: $EXOZ ), used a May 2026 investor presentation to lay out the company’s cell free biomanufacturing platform. The platform takes the enzymes that build complex natural molecules and runs them outside the living cell, which the company says yields high purity at commercial scale and reaches molecules that are hard to extract or synthesize otherwise. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Here is how Marlett described what the platform can now do: “...we are now proving that we can actually make these and scale them, which is a first, which was sort of the dream of synthetic biology but was never really delivered upon. And we’re demonstrating that we can manufacture them at scale. So many of these people are using synbio and making human gram quantities and we’re now demonstrating that we can deliver them in ton quantities. And the big benefit of what we’re doing is it’s super pure.” The presentation also covered: • A platform that takes enzymes out of the cell and evolves them to run at industrial scale, building on more than a decade of cell free research • A focus on natural molecules that are difficult to extract or synthesize through traditional methods • Technology transfer to a third party contract manufacturer to support scale up from lab to commercial volumes • The ability to engineer more potent and more bioavailable analogs of the molecules it produces Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology that uses AI engineered enzymes to convert feedstocks into high value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG
1 · Reply